论文部分内容阅读
目的探讨孟鲁司特钠和氯雷他定联合治疗小儿咳嗽变异性哮喘的临床效果。方法 80例小儿咳嗽变异性哮喘患儿,随机分为观察组和对照组,各40例。对照组采用常规治疗,观察组在对照组基础上给予孟鲁司特钠和氯雷他定联合治疗。观察两组临床症状消失时间,评定治疗效果。结果观察组患儿的哮喘持续时间短于对照组,咳嗽消失时间早于对照组,观察组肺部哮鸣音消失时间早于对照组,差异有统计学意义(P<0.05)。观察组总有效率为95.0%,对照组为75.0%,观察组总有效率高于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特钠和氯雷他定联合治疗能够较早改善咳嗽变异性哮喘患儿症状,治疗效果显著,值得借鉴。
Objective To investigate the clinical efficacy of combination of montelukast sodium and loratadine in the treatment of children with cough variant asthma. Methods Eighty children with cough variant asthma were randomly divided into observation group and control group, 40 cases each. The control group was treated by conventional therapy. The observation group was treated with montelukast sodium and loratadine on the basis of the control group. Observed the disappearance of clinical symptoms of two groups, to assess the therapeutic effect. Results The duration of asthma in observation group was shorter than that in control group, and the disappearance time of cough was earlier than that in control group. The disappearance time of lung wheeze in observation group was earlier than that in control group (P <0.05). The total effective rate was 95.0% in the observation group and 75.0% in the control group. The total effective rate in the observation group was higher than that in the control group (P <0.05). Conclusion Combination of montelukast sodium and loratadine can improve the symptoms of children with cough variant asthma earlier. The therapeutic effect is remarkable and worth learning from.